Keratoacanthoma - Keratoakanthom
☆ In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
Typicam Keratoakanthom (Keratoacanthoma)
References
Keratoacanthoma (KA) Tumor cutis crebra nota est ob eius incrementum ac potentiam in se ipsa regredi. Plerumque accidit in vetustioribus, albis hominibus cum historia solis damnum. Dum chirurgicam remotionem adhibens excisis vel chirurgiae micrographicae Mohs curationis solitae est, variae optiones therapiae praesto sunt.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) is a common cutaneous tumor characterized by rapid growth and possible spontaneous regression. It most commonly affects older, fair-skinned males with significantly sun damaged skin. Although surgical removal with excision or Mohs micrographic surgery remains the standard of therapy, there are many alternative therapeutic modalities that can be utilized.
Keratoacanthoma (KA) tumor humilis gradus est qui in quibusdam glandulis in cute incipit et sub microscopio squamous cell carcinoma (SCC) similis est. Diuturna disceptatio est de an KA poni debeat forma incursionis SCC.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Keratoacanthoma (KA) is a comparatively common low-grade tumor that initiates in the pilo-sebaceous glands and pathologically mimics squamous cell carcinoma (SCC). Essentially, strong debates confirm classifying keratoacanthoma as a variant of invasive SCC. The clinical behavior of KA is hardly predictable and the differential diagnosis of keratoacanthoma and other conditions with keratoacanthoma-like pseudocarcinomatous epithelial hyperplasia is challenging, both clinically and histopathologically.
Cutaneous squamous cell carcinoma (cSCC) Secundum genus cancri frequentissimum est in hominibus, praesertim inter homines vetustiores. Surgeria typice tractabat cSCC, sed pro quibusdam aegris qui surgery habere non possunt vel non volunt, aliae optiones sicut curationes intralesionales considerari possunt. Traditionales curationes intralesionales (methotrexate or 5-fluorouracil) adhibitae sunt, sed perennem investigationem in novis accessionibus sicut intralesionales immunotherapy et oncolytica virotherapy. In hoc videbimus varias curationes intralesionales pro cSCC, e rationibus classicis ad incisionis ora consilia discurrentibus.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Cutaneous squamous cell carcinoma (cSCC) is the second most frequent cancer in humans, and it is especially common in fragile, elderly people. Surgery is the standard treatment for cSCC but intralesional treatments can be an alternative in those patients who are either not candidates or refuse to undergo surgery. Classic intralesional treatments, including methotrexate or 5-fluorouracil, have been implemented, but there is now a landscape of active research to incorporate intralesional immunotherapy and oncolytic virotherapy into the scene, which might change the way we deal with cSCC in the future. In this review, we focus on intralesional treatments for cSCC (including keratoacanthoma), from classic to very novel strategies.
Sub microscopio, keratoakanthom (keratoacanthoma) carcinomate squamosa valde propinqua. Cum nonnulli pathologi keratoakanthom (keratoacanthoma) quasi distinctum entitatem et non malignitatem indicant, circa 6% orci et histologici keratoakanthom (keratoacanthoma) progrediuntur ad carcinomata cellae squamae incursivae et infestae.
○ Diagnosis et curatio
#Dermoscopy
#Skin biopsy